Day OneTuesday, March 10, 2026 - ET (Eastern Time, GMT-05:00)

Join industry leaders for an insightful examination of the current global life science landscape, with a special focus on the United States' competitive position. This panel brings together experienced life science executives to provide a comprehensive view of funding trends and strategic opportunities

• Who is stepping up to fill gaps in early-stage funding, and what new investment models are emerging?
• Which life science companies and therapeutic areas are attracting investor capital in today's market?
• Practical strategies for companies to navigate and thrive in the current funding environment
• How has the rise of China as a life science powerhouse reshaped the global investment patterns, and where does the US and Europe stand in comparison?

• Exploring why private companies are dominating the M&A landscape and how this trend is reshaping biopharma exit strategies
• Practical steps to make your company an attractive target, from building a compelling pipeline to demonstrating market readiness
• Insights into how to navigate mergers and acquisitions, including deal structuring, negotiations, and integration planning
• Key factors driving decisions between acquiring individual assets versus entire pipelines, and how companies can align their strategy with buyer priorities

This comprehensive masterclass equips life science entrepreneurs with essential strategies to build, protect, and leverage intellectual property assets that drive company valuation and create sustainable competitive advantages in the rapidly evolving healthcare innovation landscape.

This masterclass will:

• Provide practical frameworks for developing a strategic IP portfolio that aligns with your business objectives and therapeutic focus

• Deliver expert guidance on patent strategies specific to various life science modalities including biologics, gene therapies, and digital health

• Equip you with effective approaches to navigate freedom-to-operate challenges and competitive IP landscapes

• Demonstrate how to leverage IP assets in fundraising, partnerships, and exit strategies to maximize company valuation

• Guide you through critical decisions on global filing strategies and cost-effective IP management for resource-constrained startups

• Include interactive sessions with experienced IP attorneys and life science executives who have successfully built valuable IP portfolios

• Which markets are currently most desirable for startups and why?
• Navigating varied and complex regulatory requirements across China, Europe, and the Middle East
• Discussing the importance of forming local alliances and strategic collaboration partners
• Tailoring your business and commercialization plans to fit the unique dynamics of each regional market
• Understanding how to safeguard your intellectual property and comply with regional data privacy laws while expanding your global footprint

• Overview of the growth we’ve seen in the space in recent years
• Highlighting breakthroughs in diagnostics, therapeutics, and digital health solutions tailored to women’s needs
• Understand how investors are shifting focus toward women’s health and what it means for startups
• Discussing how low reimbursement rates affect women's health and what needs to be done to fix this
• A look at home advancing women's brain health is a strategic pathway to strengthening global brain care

• Strategies for securing investment in a competitive and evolving market
• Discussing the key metrics that define viability and ROI in TechBio
• Identify what sets strong TechBio companies apart from short-lived trends
• Examine the long-term potential of TechBio as a profitable business model
• Gain insights into what investors prioritize when evaluating TechBio opportunities

• How to adapt exit strategies in a cautious and unpredictable financial landscape
• Beyond the IPO - exploring alternative pathways to liquidity that are gaining traction in today’s market
• Advice from industry leaders on mastering your exit strategy in a shifting environment
• How to be “exit ready” at all times by maintaining strong financials, a clear growth narrative, and a well-defined plan for providing a return to stakeholders

As life sciences evolve, corporate venture capital (CVC) is becoming a critical driver of innovation. With big pharma and tier 1 medtechs shifting focus from internal R&D to external innovation, CVCs are playing a pivotal role in identifying and funding transformative solutions. This panel brings together CVC leaders to share insights into their investment strategies, decision-making processes, and how startups can successfully engage with these global giants

• How do CVC’s balance strategic goals with financial returns?
• Understand the focus areas and key factors that guide CVC decision-making
• Building strong, mutually beneficial relationships with CVCs